Perspective Therapeutics (CATX) Construction in Progress (2011)
Perspective Therapeutics' (CATX) quarterly Construction in Progress came in at $123613.0 in Q2 2011.
Analysis
Perspective Therapeutics (CATX) Construction in Progress (2011) Analysis & Trends
Perspective Therapeutics has disclosed Construction in Progress across 1 years of filings, most recently posting $123613.0 for Q2 2011.
- In Q2 2011, Construction in Progress changed N/A year-over-year to $123613.0; the TTM figure through Jun 2011 stood at $123613.0 (changed N/A YoY), while the FY2011 annual figure was $123613.0, changed N/A from the prior year.
- Construction in Progress came in at $123613.0 for Q2 2011 at Perspective Therapeutics.
- In the past five years, Construction in Progress ranged from a high of $123613.0 in Q2 2011 to a low of $123613.0 in Q2 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |